outside of the Sanders-Brown Center on Aging building

Sanders-Brown Center on Aging

Verda Davis

Our Mission

Improving the health of the older adults in Kentucky and beyond through research dedicated to understanding the aging process and age-related brain diseases, and education, outreach, and clinical programs that promote healthy brain aging.

2025 Marks the 40th Anniversary of the UK Sanders-Brown Center on Aging Alzheimer's Disease Research Center

Forty years ago, the National Institute on Aging launched its ADRC grants program, and Sanders-Brown was among the prestigious first class of just 10 awardees. We continue to carry that designation, world-renowned for our significant contributions to the field of aging.  To Learn more about the history, goals, accomplishments, and the celebration planned:

CLICK HERE

Applications Now Being Accepted

The Sanders-Brown NIH T32 grant (T32 AG078110) entitled “Translational Research in Alzheimer’s and Related Dementias (TRIAD)” will have 2 predoc and 1 postdoc slots open for appointment on August 1, 2025 or slightly later. Applications for support are due on June 16, 2025.  

The emphasis of the grant is on providing cross-disciplinary training from bench to bedside, i.e., spanning the discovery continuum from molecular/biochemical approaches, preclinical translational approaches, and clinical research. The thematic focus is on risk factors for dementia, including cerebrovascular disease, neuroinflammation, acute brain injury, and lifestyle/genetic risk factors. Trainees with diverse research backgrounds beyond standard wet-lab neuroscience, such as bioinformatics, biostatistics, engineering, epidemiology, social sciences, engineering, and community based and human research studies, are strongly encouraged to apply.

We would love to see an application from you and your outstanding trainee!  This can also be a great recruiting tool for prospective postdocs.

 If you have any questions or would like to discuss the T32 in more detail, please contact Linda Van Eldik, at 859-257-5566, linda.vaneldik@uky.edu or Paul Murphy, 859-218-3811, michael.murphy@uky.edu.

DOWNLOAD THE RFA HERE

SB exterior

Drug studied at UK is first disease-modifying therapy in U.S. approved to treat Alzheimer’s

In 2023, the FDA fully approved Leqembi (lecanemab) for Alzheimer’s treatment. UK’s Sanders-Brown Center on Aging has studied this and similar drugs for over a decade.

75%
Increase in Funding
NIH funding to the Sanders-Brown Center on Aging increased from $13.3 million to $23.4 million in one year, a remarkable 75% increase in funding.
125
Employees
Beginning with only three faculty members, the Center has grown to more than 125 employees and to be one of the nation's leading centers on aging.

Learn More

Access the latest information about the Sanders-Brown Center on Aging on social media pages: Facebook  Bluesky  X (formerly Twitter)  YouTube

Listen to Sanders-Brown Center on Aging experts on the Mind Matters podcast on Spotify, Apple, and iHeart Media.